Chargement...

Robocath secures €40 million series C financing round to deploy its operations development plan

29 April 2020

Rouen, France, April 29, 2020 – Robocath, a company that designs, develops and commercializes cardiovascular robotic systems for the treatment of vascular diseases, today announces it has secured €40 million ($43M) in a series C round of financing. This was led by MicroPort Scientific Corporation (HKG:853), a major listed industrial player in the cardiovascular field, with participation from institutional investors (Zhejiang Silk Road Fund, Luxembourg CLIIF managed under TUS-Holdings, CS Group and Anaxago) as well as existing Robocath investors (1).

Learn more

Robocath successfully completes first robotic coronary angioplasties in Germany with R-One™

21 January 2020

Rouen, France, January 21, 2020 – Robocath, a company that designs, develops and commercializes cardiovascular robotic systems for the treatment of vascular diseases, today announces it has successfully completed its first robotic coronary angioplasties with R-One™ in Germany. The Percutaneous Coronary Interventions (PCI) were performed by Prof. Michael Haude, a recognized and highly experienced interventional cardiologist at Rheinland Klinikum Neuss Lukaskrankenhaus, and his team.  

Prof. Michael Haude, Director of Medical Clinic I at Rheinland Klinikum Neuss Lukaskrankenhaus, said, “I’m proud…

Learn more

Robocath successfully completes first robotic coronary angioplasties in Africa

16 December 2019

Rouen, France, December 16, 2019 – Robocath, a company that designs, develops and commercializes cardiovascular robotic systems for the treatment of vascular diseases, today announces it has successfully completed six robotic coronary angioplasties with R-One™, a first for the continent of Africa. These Percutaneous Coronary Interventions (PCI) were performed by Dr Faizel Lorgat, an interventional cardiologist at the Netcare Christiaan Barnard Memorial Hospital, Cape Town, as part of a distribution agreement with Vertice MedTechGroup. These procedures will lead to the…

Learn more

Robocath successfully carries out its first robotic coronary angioplasties in humans

24 September 2019

The procedures were performed at Rouen University Hospital and Clinique Pasteur in Toulouse (France) and precede the first clinical study of its kind to be conducted in Europe

Rouen, September 24, 2019 – Robocath, a company that designs, develops and commercializes cardiovascular robotic systems for the treatment of vascular diseases, today announces the success of its first two coronary angioplasties performed with assistance from its R-One™ robotic platform. The procedures were performed in France at Rouen University Hospital by Professor…

Learn more

Robocath raises €5 million and announces the appointment of Lucien Goffart as new CEO

3 September 2019

Rouen, September 3, 2019. – Robocath, a company that designs, develops and commercializes cardiovascular robotic systems for the treatment of vascular diseases, announces today that it has raised €5 million ($5.5M) to support the rollout of its robotic platform in strategic European target markets. The company has also hired Lucien Goffart as CEO.

With twenty years of experience in interventional cardiology, Lucien Goffart has held a number of key positions in leading companies in the sector. He also has a…

Learn more

Robocath strengthens its medical advisory board with international interventional cardiology experts

21 May 2019

Rouen, France, May 21, 2019 – Robocath, a company that designs, develops and commercializes cardiovascular robotic systems for the treatment of vascular diseases, announces today that Pr Haude, Dr Lorgat and Pr Nef have joined its medical advisory board. All are global experts and recognized leaders in interventional cardiology.

The board plays a key role in defining the clinical strategy of the company. Their clinical work will contribute to the worldwide growth of robotics in interventional cardiology.

Philippe Bencteux, president…

Learn more

Robocath obtains CE marking for R-One™, its robotic-assisted solution for treating coronary diseases

26 February 2019

Rouen, France, February 26, 2019 – Robocath, a company that designs, develops and commercializes cardiovascular robotic systems for the treatment of vascular diseases, announces today that it has obtained CE certification for its R-One™ robotic device. As a result, it can begin commercialization in Europe and the Middle East.

R-One™ is the first European robotic solution to obtain the CE mark in the field of interventional cardiology. The robot assists interventional cardiologists in stenting (angioplasty) by enabling precision technologies that…

Learn more

Robocath’s R-One™ robot acquired by the Medical Training & Testing Center in Rouen for future healthcare practitioner training

14 January 2019

Robocath, a company that designs, develops and commercializes cardiovascular robotic systems for the treatment of vascular diseases, announces today that the Medical Training and Testing Center (MTC) in Rouen will use its R-One™ robot for future training. Founded in 2017, the MTC is a new center dedicated to training healthcare professionals in a number specialties, with special focus on new technologies.

The R-One™ robot at the MTC will enable the training of future potential users and ensure optimal use by…

Learn more

Robocath demonstrates safety and efficacy of R-One

22 May 2018

100% technical success and no MACE[1] scored in first pre-clinical randomized trial

Robocath, a company that designs, develops and commercializes cardiovascular robotic systems for the treatment of vascular diseases, announces today during the EuroPCR congress that its first robotic solution, R-OneTM, met all its primary efficacy and safety endpoints in the first pre-clinical study.

The prospective, randomized, controlled, multi-operator study evaluated the efficacity and safety of the robotic system compared to a manual procedure. Results showed that…

Learn more

Robocath sets up medical advisory board composed of International interventional cardiology Key Leaders

30 January 2018

Rouen, January 30, 2018 – Robocath, a company that conceives and develops cardiovascular robotic systems for the treatment of vascular diseases, announces today the creation of its medical advisory board including global experts and recognized leaders in interventional cardiology.

This committee will help define the clinical strategy of the company and more broadly contribute to the development of future generations of Robocath’s robotic system products.


Philippe Bencteux, president and founder of Robocath, said: “I’m particularly proud and pleased…

Learn more
Subscribe to our newsletter